These findings may say a lot more about a patient's long-term health than clinicians realized. 

Biotronik's Freesolve technology, which gained CE mark approval in February, is designed to maximize blood flow and minimize the post-implantation risks of stent thrombosis and target lesion revascularization.

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

The Heart Failure Society of America shared a new scientific statement about this topic, noting that many patients may require additional help.

This is a Class I recall, which means using the device “may cause serious injuries or death.” However, the FDA emphasized that this is a correction and not a product removal.

President Joe Biden signed a funding bill worth $460 billion on March 9, but it only included partial relief for cardiologists, cardiac surgeons and other cardiology professionals. 

The FDA made a special announcement about its decision, describing the news as "a major advance for public health."

“Aspirin is no longer a one-size-fits-all preventive tool for older adults," according to one specialist with Michigan Medicine.